



When startups raise early-stage capital, they often skip traditional equity rounds in favor of more flexible instruments. Two of the most common tools: SAFEs (Simple Agreements for Future Equity) and convertible notes. Each has unique pros, cons, and investor appeal.
In this article, we’ll break down how they work, when to use each, and how to navigate investor expectations—especially when prepping for a Global Capital Network (GCN) pitch.
Created by Y Combinator in 2013, a SAFE is a simple agreement where investors provide capital now in exchange for the right to future equity—typically at your next priced round.
Key Features:
Pros:
Cons:
💡 According to Carta, over 50% of early-stage U.S. startups now raise their first $500K–$2M using SAFEs.
A convertible note is a debt instrument that converts into equity in the future, typically during a priced round. It’s a loan that turns into shares—plus interest.
Key Features:
Pros:
Cons:
The mechanics are easier to judge with numbers. The figures below are hypothetical and simplified, and real documents vary, so always model your own terms.
For example, if an angel invests $100,000 on a SAFE with a $4M valuation cap, and your next priced round values the company at $8M, the SAFE converts at the cap. That means the angel pays roughly half the share price new investors pay, and receives about twice as many shares for the same money. Nothing is owed in the meantime, and there is no date by which the company must convert or repay.
Now take the same $100,000 as a convertible note with the same $4M cap, a 6% annual interest rate, and an 18-month maturity. If the priced round happens at month 18, roughly $9,000 of interest has accrued. The investor converts about $109,000, not $100,000, at the cap price. If no priced round happens before maturity, the founder and investor have to agree what happens next: an extension, a conversion on agreed terms, or, in the worst case, a demand for repayment.
The cap usually matters far more than the instrument. Interest on a note adds a modest amount of extra dilution, while the maturity date adds a deadline. The real trade-off is between the simplicity of a SAFE and the structure and protection of a note.
For angels, the choice affects both protection and paperwork. A note gives a clearer legal claim and a deadline that prompts a conversation if the company stalls. A SAFE is quicker and simpler but relies more on trust that a priced round will come. Either way, the cap and discount drive most of the outcome, so focus negotiation there.
Many angels and micro-VCs are now familiar with both tools. Some GCN investors may lean toward SAFEs due to simplicity, while others prefer notes for legal protection.
The best approach? Ask your lead investor what they’re most comfortable with, and model dilution scenarios either way.
“It’s not just about the docs—it’s about what builds trust with your first checks.”
— Startup Counsel, TechCrunch Early Stage



.png)




